Evidence map›Paper›PMID 33921361›Full record

ArticleLife (Basel, Switzerland)2021

Is Preptin a New Bone Metabolism Parameter in Hemodialysis Patients?

Małgorzata Kałużna, Krzysztof Pawlaczyk, Krzysztof Schwermer, Krzysztof Hoppe, Aisha Yusuf Ibrahim, Magdalena Czlapka-Matyasik, Elżbieta Wrotkowska, Katarzyna Ziemnicka, Andrzej Oko, Marek Ruchała

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06594042 (Serum Preptin Level and Its Relationship With Bone Mineral Disease in Chronic Kidney Disease Patients), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06594042 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Serum Preptin Level and Its Relationship With Bone Mineral Disease in Chronic Kidney Disease Patients

TypeobservationalSponsorAssiut UniversityRan2025 to 2026Enrolled96ConditionsPreptinArmsserum preptin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Małgorzata KałużnaDepartment of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0002-2116-4384
Krzysztof PawlaczykDepartment of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0001-6237-0814
Krzysztof SchwermerDepartment of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.
Krzysztof HoppeDepartment of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0002-5123-9228
Aisha Yusuf IbrahimDepartment of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.
Magdalena Czlapka-MatyasikDepartment of Human Nutrition and Dietetics, Poznan University of Life Sciences, 60-624 Poznań, Poland.ORCID 0000-0002-6085-4855
Elżbieta WrotkowskaDepartment of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.
Katarzyna ZiemnickaDepartment of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0001-5377-8834
Andrzej OkoDepartment of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.
Marek RuchałaDepartment of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0002-6296-7220
Poznan University of Medical Sciences · PLUniversity of Life Sciences in Poznań · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreptin is a bone-anabolic pancreatic peptide hormone. Its role in bone metabolism has been studied in rats and in patients with diabetes, but its levels and significance in bone metabolism in hemodialyzed (HD) patients is unknown.

methodsThe relationships between preptin and anthropometric and biochemical parameters related to bone metabolism were studied in 73 patients on chronic hemodialysis (48 males, 25 females; mean age of 57 years; HD vintage of 69.7 months). Of these subjects, 36 patients had diabetes or impaired glucose tolerance (DM/IGT), and 37 patients had normal glucose tolerance (NGT). Dual-energy X-ray absorptiometry of the femoral neck and lumbar spine were also performed.

resultsNo differences were observed in preptin levels between DM/IGT and NGT HD patients. Preptin was positively correlated with HD vintage (r = 0.312,

conclusionsThe results indicate that preptin may reflect on bone and mineral metabolism disturbances seen in HD patients. The significant correlation of preptin with PTH and osteocalcin suggests that preptin may be important in indirect measurement of bone turnover in HD patients.

Indexed as

bone markerchronic kidney disease (CKD)dual-energy X-ray absorptiometry (DEXA)end-stage renal disease (ESRD)hemodialysis (HD)hyperparathyroidismosteocalcinpreptin

Identifiers

PMID33921361
PMCPMC8069327
OpenAlexW3155809971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.